放射联合西妥昔单抗对前列腺癌细胞系DU145的功能与突变分析
该体外研究在前列腺癌细胞系DU145与A431中分析放射联合西妥昔单抗对增殖、克隆形成与凋亡的影响。DU145中4 Gy照射使细胞数减少44%,联合西妥昔单抗后减少55%;西妥昔单抗未显著改变放射后的生长抑制或存活分数,仅见凋亡细胞比例的微小变化。未检测到RAS突变或HER2扩增,但发现TP53 c.820G>T突变。
要点
- DU145中4 Gy照射细胞数减少44%,联合西妥昔单抗减少55%,联合未显著增敏。
- 西妥昔单抗未显著改变放射后存活分数,仅见凋亡比例微小变化。
- 未检出RAS突变或HER2扩增,检出TP53 c.820G>T突变。
核心结论
- 放射可抑制DU145增殖与克隆生长并诱导凋亡,但西妥昔单抗未产生显著放射增敏效应。
- 西妥昔单抗长期处理未诱导耐药突变。
研究设计与样本
- 体外研究,使用前列腺癌细胞系DU145与A431。
- 采用增殖实验、克隆形成单位实验与annexin-V凋亡实验评估放射与西妥昔单抗效应。
- 检测放射及西妥昔单抗处理后pEGFR与pERK1/2蛋白表达变化。
- 采用NGS分析西妥昔单抗长期处理的影响。
主要发现
- DU145中4 Gy照射后细胞数减少44%(p=0.006),4 Gy联合西妥昔单抗后减少55%(p<0.001)。
- DU145存活分数:2 Gy为0.69,4 Gy为0.41,6 Gy为0.15(各p<0.001)。
- 西妥昔单抗未显著改变4 Gy照射DU145细胞的生长抑制(p>0.05)或存活分数(p>0.05),但检测到对凋亡细胞比例的微小影响。
- 西妥昔单抗处理后western blot未检测到pEGFR与pERK1/2蛋白信号。
- 未检测到RAS突变或HER2扩增,发现TP53基因突变c.820G>T。
关键数值与推荐
- DU145细胞4 Gy照射后细胞数减少44%(p=0.006),4 Gy联合西妥昔单抗后减少55%(p<0.001)。
- DU145存活分数2 Gy为0.69、4 Gy为0.41、6 Gy为0.15,各p<0.001。
- 西妥昔单抗对4 Gy照射DU145的生长抑制与存活分数均无显著影响(p>0.05)。
- 未检出RAS突变或HER2扩增,检出TP53 c.820G>T突变。
临床怎么用
- 该体外结果提示西妥昔单抗联合放射在DU145中未显著增强放射效应,临床决策需结合更多证据。
- 抗EGFR联合放疗的增敏策略仍需进一步研究明确最佳组合。
局限性
- 研究为体外细胞系实验,结果不能直接外推至临床。
- 西妥昔单抗的放射增敏效应未显著,仅见凋亡比例的微小变化。
- 需进一步研究明确何种抗EGFR治疗策略组合可提高放射增敏效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but clinical data are not sufficient to date. METHODS: We analyzed effects of radiation and cetuximab in DU145 and A431 using proliferation, colony-forming-unit- and annexin-V-apoptosis-assays. Changes in protein expression of pEGFR and pERK1/2 after radiation and cetuximab treatment were analyzed. Using NGS we also investigated the impact of cetuximab long-term treatment. RESULTS: Cell counts in DU145 were reduced by 44% after 4 Gy (p = 0.006) and 55% after 4 Gy and cetuximab (p < 0.001). The surviving fraction (SF) was 0.69 after 2 Gy, 0.41 after 4 Gy and 0.15 after 6 Gy (each p < 0.001). Cetuximab treatment did not alter significantly growth reduction in 4 Gy radiated DU145 cells, p > 0.05 or SF, p > 0.05, but minor effects on apoptotic cell fraction in DU145 were detected. Using western blot, there were no detectable pEGFR and pERK1/2 protein signals after cetuximab treatment. No RAS mutation or HER2 amplification was detected, however a TP53 gen-mutation c.820G > T was found. CONCLUSIONS: Radiation inhibits cell-proliferation and colony-growth and induces apoptosis in DU145. Despite blocking MAP-Kinase-pathway using cetuximab, no significant radiation-sensitizing-effect was detected. Cetuximab treatment did not induce resistance-mutations. Further research must clarify which combination of anti-EGFR treatment strategies can increase radiation-sensitizing-effects.
引用
- Schneider R, Gademann G, Ochel HJ, et al. Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145. Radiat Oncol. 2021. PMID: 34321039. doi:10.1186/s13014-021-01859-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。